1361results about How to "Promote rapid formation" patented technology

A plasma 10 is generated within a film formation chamber 2, and mainly a nitrogen gas 11 is excited within the film formation chamber 2. Then, the excited nitrogen gas 11 is reacted with a diborane gas 13 diluted with a hydrogen gas, thereby forming a boron nitride film 15 on a substrate 4. Thus, the boron nitride film 15 excellent in mechanical and chemical resistance, high in thermal conductivity, and having a low relative dielectric constant κ can be formed speedily.

The present invention relates to methods of replacing nucleotides in target nucleic acid sequences using DNA-LNA chimeras. The method of the present invention provides for replacing a first nucleotide in a target sequence by exposing the target sequence to a DNA-LNA heteropolymer and thereby replacing the first nucleotide with a second nucleotide. The invention also features the DNA-LNA chimeras themselves as well as methods of making them.

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and / or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

The present invention provides methods and compositions of engineered cells for use in the continuous or transient delivery of growth factors and angiogenesis modulating agents, such as vascular endothelial growth factor (VEGF), in conjunction with constructs for replacing or augmenting organ functions. In one aspect of he invention, the genetically engineered cells can be immature cells that are capable of differentiating and assimilating into the target region. The methods of the present invention can be used to enhance vascularization locally at a target site in need of repair, growth, or implantation through the incorporation of autologous cells which have been genetically engineered to secrete a growth factor or angiogenesis modulating agent.

The present invention discloses the process of supplying high pressure (e.g., 30 atmospheres) CO that has been preheated (e.g., to about 1000° C.) and a catalyst precursor gas (e.g., Fe(CO)5) in CO that is kept below the catalyst precursor decomposition temperature to a mixing zone. In this mixing zone, the catalyst precursor is rapidly heated to a temperature that results in (1) precursor decomposition, (2) formation of active catalyst metal atom clusters of the appropriate size, and (3) favorable growth of SWNTs on the catalyst clusters. Preferably a catalyst cluster nucleation agency is employed to enable rapid reaction of the catalyst precursor gas to form many small, active catalyst particles instead of a few large, inactive ones. Such nucleation agencies can include auxiliary metal precursors that cluster more rapidly than the primary catalyst, or through provision of additional energy inputs (e.g., from a pulsed or CW laser) directed precisely at the region where cluster formation is desired. Under these conditions SWNTs nucleate and grow according to the Boudouard reaction. The SWNTs thus formed may be recovered directly or passed through a growth and annealing zone maintained at an elevated temperature (e.g., 1000° C.) in which tubes may continue to grow and coalesce into ropes.

This invention relates to novel room-temperature process for obtaining calcium phosphate, in particular hydroxyapatite, coatings and microspheres that encapsulate drugs, proteins, genes, DNA for therapeutical use. The coatings and microspheres are designed to perform a defined biological function related to drug delivery, such as gene therapy through gene delivery. A novel method for encapsulation, and subsequent controlled release of therapeutically active agents from such biofunctional coatings and microspheres is disclosed. Such coatings and microspheres are useful for side-effects free, long-term, targeted, controlled release and delivery of drugs, proteins, DNA, and other therapeutic agents.

A venous valve device provides antegrade blood flow in venous vessels of the body having dysfunctional valves; it is formed in situ from autologous vein conduit not having a valve present locally. An overlap region is formed by attaching two opposing walls of the vein together in a generally axial direction forming two tubular regions. One region provides antegrade blood flow and the other region provides a sinus cavity that is filled during the initiation of retrograde blood flow. A valve cusp is formed by attaching vessel wall together forming a commissure that extends between the two overlap regions. A single valve cusp moves toward the sinus cavity to allow antegrade blood flow and moves away from the sinus cavity to block retrograde blood flow. The venous valve can also be formed from biological tissue from an autologous, heterologous, or other tissue source and implanted interpositionally at the site of valvular incompetancy.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

An implantable stent-like device for treating and occluding arteriovascular malformations (AVMs), fistulas, varicose veins or the like. More particularly, this invention relates to an implant body that includes an open-cell shape-transformable polymer structure that provides stress-free means for occluding an AVM without applying additional pressures an any distended walls of the AVM. In one embodiment, the shape-transformable polymer is a shape memory polymer implant body that self-deploys from a temporary shape to a memory shape. In another embodiment, the shape memory polymer structure is capable of a temporary compacted shape for carrying about the struts of an expandable stent for self-deployment to occlude an aneurysm.

Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and a therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and / or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.

Methods and systems are provided for alerting users of audio and / or video broadcasts. A user of a first media player may create a tune alert message and transmit the message to a second media player. The second media player may parse or decipher the message and reconfigure a tuner module to receive and process the identified content.

The invention discloses a method for treatment and in-situ ecological restoration of a black and stink riverway by using microorganism. The invention is characterized in that target strains with pertinence are selected from sewage and then matched and combined with the existing strains to form compound microbial agents; and the sewage in the riverway is treated by using the matched compound microbial agents. In the invention, according to the specific pollution conditions of the riverway, the selected strains which are grown in the sewage are used to treat the sewage in the riverway, and the strains are matched and combined with the existing strains aiming at the pollution conditions of the water body in the riverway, so that the strains can exert synergistic effects in a microorganism sewage treatment system, thereby rapidly forming superior floras so as to decompose, absorb and transfer pollutants in the riverway and then achieving the optimum treatment efficiency. In the invention, the microorganism is firstly used to treat the water body, and then the water body is treated through the self-cleaning capability of the water body, thereby reaching the purpose of curing the exterior and the inherence and not generating secondary pollution. The method has the characteristics of safety, high efficiency, low cost, small investment and the like, and is simple to operate.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The invention comprises a composite microbial agent applicable to efficiency enhancement of common chemical industry sewage treatment systems. The composite microbial agent applicable to efficiency enhancement of the common chemical industry sewage treatment systems meets the demands on treatment on comment pollutants in existing chemical industry and environmental production as well as on establishment of functional bacteria required by a stable bacteria flora. According to one of the schemes, the composite microbial agent is composed of 108 microorganisms of three major functional types. When the composite microbial agent is added together with microbial growth promoting carriers, nutrient agents and the like into a biochemical system, the composite microbial agent can promote establishment of a complete food chain in the biochemical system through various microorganisms with special pollutant degrading capabilities and comprehensive metabolic manners to enhance utilization and metabolic decomposition of pollutants in sewage through the microorganisms, thereby achieving efficient reduction of COD (chemical oxygen demand), ammonia nitrogen, phosphorous, sulfur and like.

A MEMS vapor bubble generator with a chamber for holding liquid and a heater positioned in the chamber for heating the liquid above its bubble nucleation point to form a vapour bubble; wherein, the heater is formed from a superalloy.

A microencapsulated product comprises a core, a first shell comprising a protein and being substantially carbohydrate-free, and a second shell comprising a carbohydrate and being substantially protein-free. The double shell structure provides a strong shell that makes the microcapsule suitable for use in food products. The core can be a lipid, and in particular a structured lipid with nutritional benefits, such that the nutritional benefits can be passed on to the consumer. The microcapsules of the present invention can be used in making foods products, beverage products, and mixes for making such food and beverage products.

A bone or dental implant material in the form of a paste includes a mixture of calcium phosphate and / or calcium-containing powders and a solution that is (1) an acidic calcium phosphate solution saturated with respect to one or more calcium phosphate compounds, (2) a concentrated acid solution, or (3) salt solutions with a cationic component other than calcium. The paste is stable, resistant to washout and will form hydroxyapatite and harden relatively rapidly to a cement.

The present invention provides labeling reagents and methods for labeling primary antibodies and for detecting a target in a sample using an immuno-labeled complex that comprises a target-binding antibody and one or more labeling reagents. The labeling reagents comprise monovalent antibody fragments or non-antibody monomeric proteins whereby the labeling reagents have affinity for a specific region of the target-binding antibody and are covalently attached to a label. Typically, the labeling reagent is an anti-Fc Fab or Fab′ fragment that was generated by immunizing a goat or rabbit with the Fc fragment of an antibody. The present invention provides for discrete subsets of labeling reagent and immuno-labeled complexes that facilitate the simultaneous detection of multiple targets in a sample wherein the immuno-labeled complexes are distinguished by i) a ratio of label to labeling reagent, or ii) a physical property of said label, or iii) a ratio of labeling reagent to said target-binding antibody, or iv) by said target-binding antibody. This is particularly useful for fluorophore labels that can be attached to labeling reagents and subsequently immuno-labeled complexes in ratios for the detection of multiple targets.

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and / or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and / or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and / or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.

Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and / or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.

The invention discloses a construction method for spraying-seeding kind-loam matrix on a side slope. The construction method comprises steps of A) analyzing stability of the side slope and reinforcing the side slope, B) eliminating dangers for the side slope, C) hanging a net for a slope surface of the side slope and constructing anchor rods, D) arranging a river system for the side slope and arranging a drainage system on the side slope, E) spraying and seeding seeds on the side slope via a kind-loam matrix spraying-seeding way, and F) conducting side slope maintenance management work including covering a non-woven fabric, watering, applying fertilizer, preventing diseases and insects, supplementing seeds and post-monitoring. Two-layered spraying-seeding way is applied; through bionic operation, kind-loam matrix in the nature suitable for the side slope can be simulated; plant seed germination, root development, microorganism activity and nutrient conversion can be facilitated; plant growth development can be promoted; and great application prospect can be achieved.

A compound for non-linear optics for use at 350 nm and below. The compound includes a material for non-linear optics comprising AxM(1-x)Al3B4O12. x is larger than or equal to zero and smaller than or equal to 0.1, A is selected from a group consisting of Sc, Y, La, Yb, and Lu, and M is selected from a group consisting of Sc, Y, La, Yb, and Lu. The compound is free from a molybdenum bearing impurity of at least 1000 parts per million.

The present invention provides an injector-ignition fuel injection system for an internal combustion engine, comprising an ECU controlling a heated catalyzed fuel injector for heating and catalyzing a next fuel charge, wherein the ECU uses a one firing cycle look-ahead algorithm for controlling fuel injection. The ECU may further incorporate a look-up table, auto-tuning functions and heuristics to compensate for the rapid rotational de-acceleration that occurs near top dead center in lightweight small ultra-high compression engines as may be used with this invention. The ECU may further ramp heat input to the injector in response to engine acceleration requests and, under such circumstances, may extend its look-ahead for up to four firing cycles.

The present invention provides a heated catalyzed fuel injector that dispenses fuel substantially exclusively during the power stroke of an internal combustion engine, wherein ignition occurs in a fast burn zone at high fuel density such that a leading surface of the fuel is completely burned within several microseconds. In operation, the fuel injector precisely meters instantly igniting fuel at a predetermined crank angle for optimal power stroke production. Specifically, the fuel is metered into the fuel injector, such that the fuel injector heats, vaporizes, compresses and mildly oxidizes the fuel, and then dispenses the fuel as a relatively low pressure gas column into a combustion chamber of the engine.

Apparatus is provided that includes an ultrasound ablation system, which includes a reflection-facilitation element, configured to be placed at an extramyocardial site of a subject, and to provide an extramyocardial reflective region. The system further includes an ultrasound tool, which comprises at least one ultrasound transducer configured to be positioned within a heart chamber of the subject, and to ablate myocardial tissue by applying ultrasound energy to the myocardial tissue such that at least a portion of the transmitted energy is reflected by the reflective region onto the myocardial tissue. Other embodiments are also described.